Irreversible electroporation for the management of pancreatic cancer: Current data and future directions.

Ablation Image-guided treatment Interventional oncology Irreversible electroporation Loco-regional treatment Pancreatic cancer

Journal

World journal of gastroenterology
ISSN: 2219-2840
Titre abrégé: World J Gastroenterol
Pays: United States
ID NLM: 100883448

Informations de publication

Date de publication:
14 Jan 2023
Historique:
received: 28 09 2022
revised: 13 11 2022
accepted: 21 12 2022
entrez: 23 1 2023
pubmed: 24 1 2023
medline: 25 1 2023
Statut: ppublish

Résumé

Pancreatic cancer is currently the seventh leading cause of cancer death (4.5% of all cancer deaths) while 80%-90% of the patients suffer from unresectable disease at the time of diagnosis. Prognosis remains poor, with a mean survival up to 15 mo following systemic chemotherapy. Loco-regional thermal ablative techniques are rarely implemented due to the increased risk of thermal injury to the adjacent structures, which can lead to severe adverse events. Irreversible electroporation, a promising novel non-thermal ablative modality, has been recently introduced in clinical practice for the management of inoperable pancreatic cancer as a safer and more effective loco-regional treatment option. Experimental and initial clinical data are optimistic. This review will focus on the basic principles of IRE technology, currently available data, and future directions.

Identifiants

pubmed: 36687122
doi: 10.3748/wjg.v29.i2.223
pmc: PMC9846938
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

223-231

Informations de copyright

©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.

Déclaration de conflit d'intérêts

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Références

J Vasc Interv Radiol. 2013 Nov;24(11):1709-18
pubmed: 23891044
IEEE Trans Biomed Eng. 2006 Jul;53(7):1409-15
pubmed: 16830945
J Vasc Interv Radiol. 2017 Mar;28(3):342-348
pubmed: 27993507
Anticancer Res. 2019 May;39(5):2509-2512
pubmed: 31092446
J Surg Oncol. 2016 Dec;114(7):865-871
pubmed: 27546233
Cancer Lett. 2012 Apr 1;317(1):16-23
pubmed: 22079741
Ann Surg. 2015 Sep;262(3):486-94; discussion 492-4
pubmed: 26258317
J Cancer Res Ther. 2021 Jul;17(3):613-618
pubmed: 34269289
Nat Commun. 2019 Feb 22;10(1):899
pubmed: 30796212
HPB (Oxford). 2019 Aug;21(8):1024-1031
pubmed: 30737097
Pancreas. 2021 Oct 1;50(9):1281-1286
pubmed: 34860812
Curr Pharm Des. 2015;21(10):1249-55
pubmed: 25506899
Sci Rep. 2021 Apr 7;11(1):7584
pubmed: 33828203
Nanomedicine (Lond). 2014;9(8):1181-92
pubmed: 24024571
World J Gastrointest Oncol. 2018 Dec 15;10(12):476-486
pubmed: 30595801
J Vis Exp. 2018 Jun 8;(136):
pubmed: 29939178
Radiology. 2020 May;295(2):254-272
pubmed: 32208094
Front Oncol. 2020 Jan 22;10:6
pubmed: 32038984
Immunol Lett. 2017 Jun;186:20-27
pubmed: 28392199
Hepatobiliary Surg Nutr. 2015 Jun;4(3):211-5
pubmed: 26151062
Pancreas. 2015 Jul;44(5):791-8
pubmed: 25931252
J Surg Oncol. 2011 Jul 1;104(1):22-8
pubmed: 21360714
J Vasc Interv Radiol. 2012 Dec;23(12):1613-21
pubmed: 23177107
Cancers (Basel). 2021 Aug 04;13(16):
pubmed: 34439081
J Clin Med. 2021 Apr 10;10(8):
pubmed: 33920118
Technol Cancer Res Treat. 2007 Aug;6(4):287-94
pubmed: 17668935
Cancers (Basel). 2019 Nov 03;11(11):
pubmed: 31684186
Radiology. 2020 Jan;294(1):212-220
pubmed: 31687922
Biophys J. 1974 Nov;14(11):881-99
pubmed: 4611517
Oncoimmunology. 2021 Feb 2;10(1):1875638
pubmed: 33643692
Eur J Surg Oncol. 2014 Dec;40(12):1598-604
pubmed: 25307210
BMJ Open. 2022 May 12;12(5):e050166
pubmed: 35551086
Technol Cancer Res Treat. 2007 Feb;6(1):37-48
pubmed: 17241099
Signal Transduct Target Ther. 2020 Oct 23;5(1):215
pubmed: 33093457
Int J Surg. 2015 Sep;21 Suppl 1:S34-9
pubmed: 26118600
Front Oncol. 2022 May 25;12:843769
pubmed: 35692753
Cancers (Basel). 2020 Jul 03;12(7):
pubmed: 32635230
Technol Cancer Res Treat. 2007 Aug;6(4):307-12
pubmed: 17668938
J Vasc Interv Radiol. 2012 Jan;23(1):107-13
pubmed: 22137466
Semin Intervent Radiol. 2019 Dec;36(5):386-391
pubmed: 31798212
Lancet Oncol. 2016 Jun;17(6):801-810
pubmed: 27160474
Med Biol Eng Comput. 2017 Jul;55(7):1123-1127
pubmed: 28078482
Mol Ther Methods Clin Dev. 2015 Mar 04;2:15001
pubmed: 26029712
Cell Physiol Biochem. 2018;48(5):1882-1893
pubmed: 30092590
Tech Vasc Interv Radiol. 2020 Jun;23(2):100675
pubmed: 32591191
Front Oncol. 2021 Sep 10;11:712042
pubmed: 34568040
Cancers (Basel). 2018 Jan 10;10(1):
pubmed: 29320420
Radiology. 2010 May;255(2):426-33
pubmed: 20413755
CA Cancer J Clin. 2017 Jan;67(1):7-30
pubmed: 28055103
Front Oncol. 2020 Jul 28;10:1235
pubmed: 32850371
J Am Coll Surg. 2012 Sep;215(3):361-9
pubmed: 22726894
Pancreatology. 2020 Apr;20(3):470-476
pubmed: 32033896
HPB (Oxford). 2010 Jun;12(5):348-51
pubmed: 20590911

Auteurs

Stavros Spiliopoulos (S)

Second Department of Radiology, School of Medicine, National and Kapodistrian University of Athens, Athens 12461, Attiki, Greece. stavspiliop@med.uoa.gr.

Lazaros Reppas (L)

Second Department of Radiology, School of Medicine, National and Kapodistrian University of Athens, Athens 12461, Attiki, Greece.

Dimitrios Filippiadis (D)

Second Department of Radiology, School of Medicine, National and Kapodistrian University of Athens, Athens 12461, Attiki, Greece.

Antonella Delvecchio (A)

Unit of Hepato-Pancreatic-Biliary Surgery, "F. Miulli" Regional General Hospital, Acquaviva delle Fonti 70021, Bari, Italy.

Maria Conticchio (M)

Unit of Hepato-Pancreatic-Biliary Surgery, "F. Miulli" Regional General Hospital, Acquaviva delle Fonti 70021, Bari, Italy.

Riccardo Memeo (R)

Unit of Hepato-Pancreatic-Biliary Surgery, "F. Miulli" Regional General Hospital, Acquaviva delle Fonti 70021, Bari, Italy.

Riccardo Inchingolo (R)

Interventional Radiology Unit, "F. Miulli" Regional General Hospital, Acquaviva delle Fonti 70021, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH